National University, NU Corona or Covid-19 Vaccine Online Registration 2021 is ongoing. Every students who read in National University affiliated colleges have to submit their information for getting Covid-19 vaccine free. So are you a NU Honours, Degree or Masters student? In this case, you must register for the Covid vaccine on behalf of your college connected with the National University. Here we are describing how to submit your student information for getting covid vaccine from National University (NU). So read full article for learning about NU Corona or Covid-19 Vaccine Online Registration Process.
There are about 2254 colleges under the National University. All these colleges have a total of 20 Lakh students. All educational institutions in the country are closed for the Covid-19 epidemic. In this situation, along with other universities, the National University is trying to find a way to restart the educational institutions by tackling this problem. Moreover, the Bangladesh government has allocated a large amount of money in the current budget for education and medical sector, especially for Covid vaccine. Therefore, after confirming the Covid vaccine to the students of all the colleges affiliated to the National University, the authorities have decided to start educational activities.
In this situation, the National University has issued a notice on July 8 to list the information of the students of all the affiliated colleges. To this end, a data list of National University students is being compiled for the purpose of registering the Covid-19 vaccine.
According to the notice, In order to prevent the spread of the global epidemic Covid-19 and to avoid health risks, the students studying in all the colleges or educational institutions affiliated with the National University can fill up the given table at http://103.113.200.29/student_covidinfo/ Must be submitted by 19 July 2021.
The esteemed principals of the affiliated colleges are requested to ensure that the information table of the students of their respective colleges is filled as the matter is of national importance and urgent in relation to public health.
National University NU students can submit their own information for Corona virus vaccine registration. Because the College authority cannot submit all of their students information in this short time. So, it is the responsibility of the students to provide their own information for receiving the Covid vaccine. Next, the college authorities will verify their college lists. To register for the corona virus vaccine, students need to go to the specific web page of the national university and submit the information using the registration number and information. The procedure for applying for free CODID-19 vaccine for students at the National University is described below.
( ) , -19 ,
In order to register NU Covid-19 vaccine visit http://103.113.200.29/student_covidinfo/ web page. NU Vaccine Registration Website Link.
Then the web page (Student Covid Info) will ask you your Registration number for going next page. So, provide your registration number of NU and click on the Next button.
After that (if you have provided the correct registration number) you will be presented with your registration number and the name of your college and below will be some fields to fill in some information. E.g. Students Name, Fathers Name, Course Name, Session, Date of Birth, Mobile Number, National ID (NID), Covid-19 Vaccine taken info, Residential status.
Fill in all the information correctly. Re-verify all information. Then click the submit button. As a National University student, your NU Covid-19 Vaccine registration will be completed successfully.
Students Name: Enter your name (dont misspell).
Fathers Name: Enter your Fathers name (dont misspell).
Course Name: Enter your course name same as your NU admission registration card.
Session: Enter your session year same as your NU admission registration card.
Date of Birth: Select your Birth date like Day-Month-Year format.
Mobile Number: Enter the mobile number that you always have on or use. Because you can get all the information related to the Covid-19 vaccine on your mobile.
National ID (NID): Enter your National Identification Number (NID) number. (Voter ID Card Number).
Covid-19 Vaccine Taken Info: Have you previously applied for the Covid-19 vaccine through Surokkha website or elsewhere? If you have Covid vaccine token or have already been vaccinated, choose Yes or No from that option.
Residential Status: Select your residential status. Mention whether you live in a college residency.
Learn More About NU Corona Virus Vaccine Registration.
How do students who do not have a national identity card or do not know the number register for the National University Covid Vaccine? The way is very simple. First, those who have passed HSC and have been admitted to any college of the National University are at least 17 years of age. And at the age of 16, information was taken from everyone for the national identity card. So I hope you also went to your nearest municipality or union council and gave information. And when the voter gave the information for the ID card and gave the picture and fingerprint, they gave you the paper of a voter slip. You can get your ID card online using that voter slip.
Check your Voter ID number by using Voter Slip. Visit Voter Info Check web page.
Then search with the voter registration form slip number, date of birth and verification code. Then your national identity card number will come. Using that number, you can also get an online copy of your national identity card. If you cant, then contact Asif on Facebook. If you take out the voter ID card from us, the service charge will be applicable. Learn more about NU Vaccine Registration Without NID.
The date of National University Vaccine Registration has been extended. Many students have not yet been able to register for the Covid vaccine due to server (103.113.200.29) issues. Moreover, many students have problems with their national id card number. The Covid-19 vaccine registration time has been extended for them. The registration time for the covid vaccine for National University students has been extended till July 19. The NU Students Covid Registration extended date has been confirmed from the National University website.
Having trouble registering the Covid-19 vaccine at the National University? Do not open the NU Vaccine Registration website http://103.113.200.29/student_covidinfo/. Contact Email (formfillup.nu@gmail.com) for web pages not opened, server problems or any information. In this case you can also inform your college authorities.
NU Covid Vaccine, National University Covid Vaccine, NU Vaccine Registration.
Have you registered as a student for the covid vaccine on the National University website? Is this the end? No! Now the question is, when, where, and how will you get the coronavirus vaccine after registering Covid on the NU website? Another question that may come to mind is that in order to be vaccinated, you need to be present in your respective college? The answers to all these questions and the things you should do after registering for NU Covid are discussed below.
We know that almost all the universities have collected information from their students for the covid vaccine. In the same way, the National University is currently collecting information from the students of all the educational institutions associated with them. National University or College authorities will not vaccinate any student after registration of NUs Covid-19 vaccine. Because the coronavirus vaccine is officially given through the Surokkha website or app. So all NU students will have to re-register for the Covid vaccine using their address through the Surokkha website or app. So, when and how will NU students get vaccinated?
National University authorities are collecting student information (mobile number and national identity card number) through the Covid registration process. This activity will continue till July 12. The National University authorities will then submit the information of all these students to the Surokkha Portal. All students at the National University will then be able to make a final application for the Covid vaccine.
A few days ago, the Surokkha website added the option for university students to apply for vaccination. NU students will be able to apply for the covid vaccine after the initial information is submitted to the Surokkha portal. Will have to wait for that long.
You can check using your NID no. and date of birth on the Surokkha website every few days to find out when your information will be added to the Surokkha website. If your information is stored on the Surokkha webpage, you will have the option to apply for the vaccine.
Learn more about the application process for the Covid vaccine on the Surakkha Web.
The good news for students is that students can choose the center of their choice to get vaccinated. When applying for the coronavirus vaccine, you will be asked for some personal information such as mobile number, health information, occupation, current address, and vaccination center. In this case, everyone can get the vaccine from their nearest community hospital. You do not have to go to college or university to get vaccinated.
Learn More about:
NU Covid Vaccine Registration
Without National ID Card NU Vaccine Registration Process
NU Vaccine Registration Website Link
NU Covid Vaccine Registration Correction
Free NU Students Corona Virus Tika
103.113 NU App
Van Life: What is it like to live on wheels?
The van life phenomenon has become even more widespread since the COVID-19 era. Many people including some Israelis have taken this idea to a new level.
By DUDI FATIMER
Dieser Text stellt eine Basisinformation dar. Eine Gewhr fr die Richtigkeit und Vollstndigkeit der Angaben kann nicht bernommen werden. Aufgrund unterschiedlicher Aktualisierungsrhythmen knnen Statistiken einen aktuelleren Datenstand aufweisen.
Last updated 16 April 2020
On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. Chinese authorities identified the SARS-CoV-2 as the causative virus on 7 January 2020, and the disease was named coronavirus disease 2019 (COVID-19) by WHO on 11 February 2020. As part of WHOs response to the outbreak, a Research and Development (R&D) Blueprint has been activated to accelerate the development of diagnostics, vaccines and therapeutics for this novel coronavirus.
Under WHOs coordination, a group of experts with diverse backgrounds is working towards the development of vaccines against COVID-19.
The group makes a call to everyone to follow recommendations to prevent the transmission of the COVID-19 virus and protect the health of individuals. The group also thanks everyone for putting their trust in the scientific community.
We are scientists, physicians, funders and manufacturers who have come together as part of an international collaboration, coordinated by the World Health Organization (WHO), to help speed the availability of a vaccine against COVID-19.While a vaccine for general use takes time to develop, a vaccine may ultimately be instrumental in controlling this worldwide pandemic.In the interim, we applaud the implementation of community intervention measures that reduce spread of the virus and protect people, including vulnerable populations, and pledge to use the time gained by the widespread adoption of such measures to develop a vaccine as rapidly as possible. We will continue efforts to strengthen the unprecedented worldwide collaboration, cooperation and sharing of data already underway. We believe these efforts will help reduce inefficiencies and duplication of effort, and we will work tenaciously to increase the likelihood that one or more safe and effective vaccines will soon be made available to all.
Randy A. Albrecht, Icahn School of Medicine at Mount Sinai, USA
Mohamad Assoum, Mercy Global Health
Luigi Aurisicchio, on behalf of Takis Biotech, Italy
Dan Barouch, Center for Virology and Vaccine Research, USA
Trevor Brasel, The University of Texas Medical Branch (UTMB), USA
Jennifer L Bath, ImmunoPrecise Antibodies, Canada
Sina Bavari, Edge BioInnovation Consulting and Management, USA
Maria Elena Bottazzi, Baylor College of Medicine, Houston, USA
Gerhard Beck,Austrian Medicines and Medical Devices, Austria
Tom Brady, Flow Pharma Inc, USA
Kate Broderick, Inovio, USA
Will Brown, Altimmune Inc, USA
Dirk Busch, Maura Dandri, Dirk Heinz and Hans-Georg Kraeusslich, on behalf of the German Center for Infection Research - DZIF, Germany
Scot Bryson, Orbital Farm, Canada
Ricardo Carrin, Texas Biomedical Research Institute, USA
Miles Carroll, Public Health England, UK
Keith Chappell, University of Queensland, Australia
Daniel S. Chertow, National Institutes of Health, U.S. Department of Health and Human Services, USA
Sandra Cordo, Universidad de Buenos Aires, Argentina
Wian de Jongh, on behalf of the Prevent n-CoV consortium (AdaptVac, ExpreS2ion, Copenhagen University, Leiden University Medical Centre, Wageningen University and Tubingen University)
Natalie Dean, University of Florida, USA
Rafael Delgado, Hospital Universitario 12 de Octubre, Spain
Dimiter Dimitrov
David A. Dodd, GeoVax, Inc., USA
Paul Duprex, Center for Vaccine Research, University of Pittsburgh, USA
Luis Enjuanes; Centro Nacional Biotecnologa, Spain
Jeremy Farrar, Josie Golding, Charlie Weller, on behalf of Wellcome Trust, UK
Mark Feinberg, Swati Gupta and Ripley Ballou, on behalf of IAVI, USA
Antonella Folgori, on behalf of ReiThera, Italy
Thomas Friedrich, University of Wisconsin, School of Veterinary Medicine, USA
Simon Funnel, Public Health England, UK
Luc Gagnon, Nexelis, Canada
Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, USA
Vipin Garg, Altimmune Inc., USA
Volker Gerdts, on behalf of VIDO-Intervac, University of Saskatchewan, Canada
Nora Gerhards, Wageningen Bioveterinary Research, The Netherlands
Christiane Gerke, Head of Vaccine Programs/Head of Vaccine Innovation Development, Institut Pasteur, France
Carlo Giaquinto, Department of Women and Child Health, University of Padova, Italy
Prakash Ghimire, Tribhuvan University, Nepal
Nikolaj Gilbert, Program for Appropriate Technology in Health (PATH), USA
Sarah Gilbert, University of Oxford, UK
Marion F. Gruber, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Farshad Guirakhoo, GeoVax Inc, USA
Bart L Haagmans, Erasmus Medical Center, The Netherlands
M. Elizabeth Halloran, Center for Inference and Dynamics of Infectious Diseases, Fred Hutchinson Cancer Research Center, and University of Washington, USA
Scott Harris, Altimmune Inc, USA
Hideki Hasegawa, National Institute of Infectious Diseases, Japan
Richard Hatchett, on behalf of the Coalition for Epidemic Preparedness Innovations (CEPI), Norway
James Hayward, Applied DNA Sciences, USA
Sheri Ann Hild
Peter Hotez, Baylor College of Medicine, USA
Youngmee Jee, Seoul National University, College of Medicine, Republic of Korea
Charu Kaushic, Institute of Infection and Immunity, Canadian Institutes of Health Research (CIHR), Government of Canada
Alyson A. Kelvin, Dalhousie University, Canada
Larry D. Kerr, Office of Global Affairs, U.S. Department of Health and Human Services, USA
Bernard Kerscher, PEI, Germany
Jae-Ouk Kim, International Vaccine Institute, Republic of Korea
Seungtaek Kim, Institut Pasteur Korea, Republic of Korea
Jason Kindrachuk, University of Manitoba, Canada
Otfried Kistner, Senior Consultant and Independent Vaccine Expert, Austria
Gary Kobinger, Universit Laval, Canada
Marion Koopmans, Viroscience Department, Erasmus Medical Centre, The Netherlands
Jeroen Kortekaas, Wageningen Bioveterinary Research, the Netherlands
Philip R. Krause, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Greg Kulnis, Nexelis, Canada
Paul Henri Lambert, Centre of Vaccinology, University of Geneva, Switzerland
Nathalie Landry, Medicago Inc., Canada
Roger Le Grand, Inserm-CEA-Universit Paris Saclay, France
Robin Levis, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Mark G Lewis, Bioqual Inc, USA
Joshua Liang, Clover Biopharmaceuticals, China
Jinzhong Lin, on behalf of Fudan University, China
Ira Longini, University of Florida, USA
Shabir Madhi, University of the Witwatersrand, Johannesburg, South Africa
Jessica E. Manning, National Institutes of Health, U.S. Department of Health and Human Services, USA
Peter Marks, Director, on behalf of Food and Drug Administration/Center for Biologics Evaluation and Research
Hilary D. Marston, National Institutes of Health, U.S. Department of Health and Human Services, USA
Federico Martinn-Torres, Hospital Clnico Universitario de Santiago de Compostela, Spain
Sebastian Maurer-Stroh, on behalf of the GISAID Initiative
John W. Mellors, University of Pittsburgh School of Medicine, USA
Ali Mirazimi, Department of Laboratory medicin, Karolinska institutet, Sweden
Kayvon Modjarrad, Walter Reed Army Institute of Research, USA
Stefan O. Mueller, CureVac, Germany
Vincent J. Munster, National Institutes of Health, U.S. Department of Health and Human Services, USA
Csar Muoz-Fontela, Bernhard-Nocht-Institute for Tropical Medicine, Germany
Aysegul Nalca, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), USA
Jos Manuel Ochoa, Altimmune Inc., USA
Dave O'Connor, University of Wisconsin-Madison, USA
Lidia Oostvogels, CureVac, Germany
Nisreen M. A. Okba, Erasmus Medical Center, The Netherlands
L. Jean Patterson, National Institutes of Health, U.S. Department of Health and Human Services, USA
Joe Payne, on behalf of Arcturus Therapeutics
Jonathan Pearce, on behalf of the UK Research and Innovation (UKRI) and the Medical Research Council (MRC), UK
Stanley Perlman, University of Iowa, USA
A Canadian study has found a link between the new variants of SARS-CoV-2, particularly the Delta variant, and an increased risk of severe disease and death.
The retrospective study, by the University of Toronto and appearing in the Canadian Medical Association Journal (CMAJ), looked at 212,326 cases in Ontario from February 7 to June 27, 2021. The study authors compared the risks of hospitalization, ICU admission, and death from the VOCs with those risks from non-VOC SARS-CoV-2 strains.
The researchers screened the cases for Alpha, Beta, Gamma, and Delta VOCs. Non-VOC infections made up 22.4% of the cases. More than three-quarters of the cases were Alpha, Beta, or Gamma, while 2.8% were probably Delta.
Alpha, Beta, and Gamma variants have a mutation that increases transmission, while Delta has a mutation that increases its ability to replicate.
Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.
The authors note that before May 2021, there was no routine screening for the Delta variant, so it is likely that the numbers underestimate the prevalence of this variant.
The present study found that all VOCs increased peoples risk of hospitalization, ICU admission, and death due to COVID-19.
However, the highest risks were from the Delta variant. In the Delta cases, there was a 108% increase in the risk of hospitalization, a 235% increased risk of ICU admission, and a 133% higher risk of death, compared with the original variant.
These effects were present even when the researchers adjusted the data for factors such as age, sex, vaccination status, and comorbidities.
Prof. William Schaffner, infectious diseases specialist at the Vanderbilt University Medical Center in Nashville, TN, commented:
This important study from Canada reinforces the serious impact the Delta variant is having. It is well recognized that Delta is more contagious than other virus variants. This new study convincingly reinforces the finding that it also causes more severe disease.
The Delta variant is now the dominant variant in the European Union, the United Kingdom, and the United States.
The findings of the present study corroborate those of the studies in England, Scotland, and Singapore that have also shown increased risks from the Delta variant.
Speaking to Medical News Today, Dr. Christopher Coleman, assistant professor of infection immunology at the University of Nottingham in the U.K., highlighted the international relevance of the study.
He said, Although this [Canadian] study has some limitations, as acknowledged by the authors, this is exactly the kind of study that helps build a picture by showing that similar observations can be observed in a lot of different circumstances.
It is not something unique about the U.K. that means the Delta variant is associated with more dangerous infections only here, he added.
Some good news from this study is that vaccination, both partial and complete, reduced the risk of severe disease and death from all the VOCs. During the course of the study, as vaccination numbers increased, hospitalizations, ICU admissions, and deaths decreased.
These results from Canada now add to those from studies from England, Scotland, and Singapore, all showing that Delta infection causes more severe disease. Fortunately, our currently available vaccines continue to provide good protection against severe Delta infections.
Prof. William Schaffner
The authors highlight that these VOCs have led to a pandemic that is larger and more deadly than it would otherwise have been.
Dr. Kirsten Patrick, interim editor-in-chief of the CMAJ, observed that most COVID-19 patients who required critical care were unvaccinated, but said, The virus has become smarter and more dangerous, which means that we need to be smarter too.
She stressed that we must use all the tools at our disposal to prevent future lockdowns. As well as boosting vaccination rates, governments must continue with measures such as extending vaccine mandates and passports, ensuring global vaccine delivery, and continuing to identify, track, and control outbreaks.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.
Sign up for The Brief, our daily newsletter that keeps readers up to speed on the most essential Texas news.
Texas Republican gubernatorial candidate Allen West, who is not vaccinated against COVID-19, tweeted on Saturday that he may be admitted to the hospital after a chest X-ray showed he has pneumonia caused by the virus.
Theres a concern about my oxygen saturation levels, which are at 89 and they should be at 95, West tweeted, adding in a follow-up tweet, My chest X-rays do show COVID pneumonia, not serious. I am probably going to be admitted to the hospital.
Earlier in the day, Wests campaign tweeted that his wife, who is vaccinated against COVID-19, had tested positive for the virus on Friday. In that tweet thread, the campaign said he was experiencing a low grade fever and light body aches and that he was canceling in-person events until he was in the clear. In the same thread, the campaign also said that West was taking hydroxychloroquine and ivermectin.
The U.S. Food and Drug Administration has said both drugs can cause serious health problems for people who take the drugs to attempt to treat COVID-19.
Hydroxychloroquine is an anti-malaria drug that the FDA has said has no benefit for decreasing the likelihood of death or speeding recovery. Ivermectin is a drug used to treat parasites in humans and animals; the FDA has said that Currently available data do not show ivermectin is effective against COVID-19.
West tweeted that he and his wife both completed monoclonal antibody treatment and were "in the observation period."
Wests campaign said in the tweets that he believes getting vaccinated against COVID-19 should be a personal choice.
On Oct. 7, West tweeted a photo from an event he attended for Mission Generation, an evangelical organization, in Seabrook, outside of Houston, describing it as a packed house. The two photos West shared depicted attendees without masks.
West represented Florida in Congress from 2011 to 2013 before moving to Texas in 2014 to become the CEO of the National Center for Policy Analysis, a Dallas think tank that shuttered three years later.
Last year, West was elected to be the state party chair, a position he resigned in June to challenge Gov. Greg Abbott in the Republican primary next year.
The White House allocated an additional $1 billion to buy millions of rapid at-home COVID-19 tests earlier this week.
Why it matters: Rapid tests can quickly determine whether you're infected with COVID-19 and at risk of spreading it to others, but lack of funding and slow approval has led to a dire shortage.
Driving the news: White House COVID-19 response coordinator Jeffrey Zients told reporters on Wednesday that the new funding as well as an additional $2 billion allocated in September will quadruple the number of available tests over the next few months.
How it works: Rapid antigen tests which can deliver results in as little as 15 minutes are particularly useful for the current moment.
The catch: In part because of that utility, however, rapid tests have become increasingly difficult to find.
What's next: This week, the FDA also authorized a new lab-based test from PerkinElmer that can detect COVID-19 as well as influenza and respiratory syncytial virus a capability that should be especially useful this winter.
Illinois health officials on Friday reported 19,244 new COVID-19 cases in the past week, along with 209additional deaths and over 251,000 new vaccine doses administered.
In all, 1,650,108 cases of coronavirus have been reported in the state since the pandemic began, according to the latest data from the Illinois Department of Public Health. The additional deaths reported this week bring the state to 25,224 confirmed COVID fatalities.
The state has administered 903,198 tests since last Friday, officials said, bringing the total to nearly 33 million tests conducted during the pandemic.
The states seven-day positivity rate on all tests dropped to 2.1% from last week 2.2% and 2.7% the week before, officials said. The rolling average seven-day positivity rate for cases as a percentage of total tests also dropped to 2.6% from 2.8% last week and 3.7% the week before.
Over the past seven days, a total of 251,287doses of the coronavirus vaccine have been administered to Illinois residents. The latest figures brought the states average down to 35,898 daily vaccination doses over the last week, per IDPH data.
More than 14.8 million vaccine doses have been administered in Illinois since vaccinations began in December. More than 54% of Illinois resident are fully vaccinated against COVID-19, with more than 69% receiving at least one dose.
As of midnight Thursday, 1,653 patients were hospitalized due to COVID in the state. Of those patients, 412are in ICU beds, and 209are on ventilators.
'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"
Instruction
75F
This story will be updated.
Fivemore Mainers have died as health officials on Saturday reported another 600coronavirus cases across the state.
Saturdays report brings the total number of coronavirus cases in Maine to 94,948,according to the Maine Center for Disease Control and Prevention. Thats up from 94,348 on Friday.
Of those, 67,648have been confirmed positive, while 27,290were classified as probable cases, the Maine CDC reported.
The statewide death toll now stands at 1,075.
The number of coronavirus cases diagnosed in the past 14 days statewide is 7,759. This is an estimation of the current number of active cases in the state, as the Maine CDC is no longer tracking recoveries for all patients. Thats down from 7,762 on Friday.
The new case rate statewide Saturday was 4.48 cases per 10,000 residents, and the total case rate statewide was 709.41.
Maines seven-day average for new coronavirus cases is 500.7, down from 519.9 the day before, down from 609.9 a week ago and up from 357.6 a month ago. That average peaked on Jan. 14 at 625.3.
The most cases have been detected in Mainers younger than 20, while Mainers over 80 years old make up the majority of deaths. More cases have been recorded in women and more deaths in men.
So far, 2,590Mainers have been hospitalized at some point with COVID-19, the illness caused by the new coronavirus. Additional information regarding those hospitalizations wasnt immediately available.
Cases have been reported in Androscoggin (10,099), Aroostook (3,521), Cumberland (20,859), Franklin (1,995), Hancock (2,474), Kennebec (9,055), Knox (1,739), Lincoln (1,666), Oxford (4,648), Penobscot (11,258), Piscataquis (1,215), Sagadahoc (1,840), Somerset (3,814), Waldo (2,170), Washington (1,602) and York (16,991) counties.Additional information about two cases was not immediately available.
As of Saturday morning, the coronavirus had sickened 44,291,158people in all 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and the U.S. Virgin Islands, as well as caused 712,698deaths, according to the Johns Hopkins University of Medicine.
More articles from the BDN
